May. 12 at 6:27 PM
$ELDN Shelf is simply preparation
This is also very plausible. Companies often activate shelves before:
partnership negotiations,
Phase 3 planning,
strategic updates,
or increased investor visibility.
And honestly, Eledon is no longer just a “kidney transplant story” in the eyes of many investors. The market is starting to connect:
kidney transplant,
islet cell/T1D,
broader immune modulation,
metabolic advantages over tacrolimus,
and potentially cleaner long-term safety.
